Tetra Pharm Technologies is a Danish biopharmaceutical company with a mission to improve quality of life for our patients through affordable, high-quality products.

Our vision is to become a leader in research and development of pharmaceutical drugs for the treatment of psychiatric, neurodegenerative, and metabolic disorders.

Tetra Pharm Technologies was founded in 2018 by Martin Rose and Jesper Breum who both held leading positions in a number of global pharmaceutical companies.

Based on their experience from the pharmaceutical industry, Martin and Jesper decided to explore their interest in and curiosity for the central nervous system (CNS) and its inherent potential for improving quality of life for patients suffering from neurological diseases , and mental health disorders.

The company headquarter is located in Copenhagen, firmly within Medicon Valley – the leading international life science cluster spanning the Greater Copenhagen region and southern Sweden.

2018
- Founded by Martin Rose and Jesper Breum

2019
- Establish corporate infrastructure and initiates identification of therapeutic objectives

2020
- Receives authorization from the Danish Medicines Agency
- Opens R&D site in Hillerød

2021
- Secures €2 million in Seed round

2022
- Submits first patent applications

2023
- Secures €14M in a series A round

- Develops product for Partner as CDMO contract in Germany

- Inaugurates 4,000 sqm R&D and production facility in Denmark

- Completes pre-clinical trial of TPT0301 (for chronic pain)

2024
- Compound for appetite suppression, TPT0701, advances into preclinical testing

- Tetra Pharm Technologies and Glysious Announce Collaboration

- Enters Partnership with Kvantify to Accelerate the Discovery of Novel Drug Candidates